Charles Sternberg, Assistant Editor05.26.21
Ori Biotech, an innovator in cell and gene therapy manufacturing, and Vineti, a provider of digital enterprise platforms for cell and gene therapy supply chains, are partnering to produce a fully pre-integrated solution to modernize, fast-track, and streamline the manufacture and delivery of cell and gene therapies (CGTs).
Advanced therapies, such as cell therapies, gene therapies, and personalized cancer vaccines, require infrastructure as advanced as their science. However, systems to manage the production of cell and gene therapies are outdated and often manual. This can severely hamper data clarity, scale, speed, and patient safety. The CGT industry now requires a new level of visibility, detail, and access across each product and facility within the supply chain.
Helping Treatments Get to Patients Faster
This global, non-exclusive partnership between Ori and Vineti will provide important solutions for therapy developers, contract manufacturers, and academic centers.
Ori is revolutionizing CGT manufacturing through a proprietary platform that incorporates automation and digitalization of production data. Ori is working with leaders across the cell and gene therapy industry to integrate and secure the entire product journey. Vineti’s Personalized Therapy Management (PTM) platform is a proven purpose-built, enterprise-grade digital solution for advanced therapy data and supply chains, which will integrate with Ori’s platform to deliver a next-generation digital supply chain management system that supports therapies from clinical-phase to commercial distribution at scale.
“The pre-integration of Vineti’s Chain of Identity and Chain of Custody systems with the Ori full-stack platform is critical to help ensure our customers have full end-to-end visibility, control, and insights into their processes,” said Ori Biotech CEO Jason C. Foster. “The addition of established technologies in such a critical aspect of CGT manufacturing allows us to enable our partners across the industry to develop and commercialize therapies as safely, cost effectively, and quickly as possible to reach the large numbers of patients who need these therapeutic alternatives.”
“Advanced therapies are at a point where they require true industrialization, with the best digital tools and a connected ecosystem,” said Vineti CEO and co-founder Amy DuRoss. “We’re very excited to partner with Ori Biotech to deliver our shared next-generation vision and ultimately help breakthrough treatments get to patients faster.”
This partnership follows on from Ori’s continuous growth since closing a $30 million Series A funding round in 2020, and Vineti’s release of its PTM Essentials solution for advanced therapy clinical trials.
Advanced therapies, such as cell therapies, gene therapies, and personalized cancer vaccines, require infrastructure as advanced as their science. However, systems to manage the production of cell and gene therapies are outdated and often manual. This can severely hamper data clarity, scale, speed, and patient safety. The CGT industry now requires a new level of visibility, detail, and access across each product and facility within the supply chain.
Helping Treatments Get to Patients Faster
This global, non-exclusive partnership between Ori and Vineti will provide important solutions for therapy developers, contract manufacturers, and academic centers.
Ori is revolutionizing CGT manufacturing through a proprietary platform that incorporates automation and digitalization of production data. Ori is working with leaders across the cell and gene therapy industry to integrate and secure the entire product journey. Vineti’s Personalized Therapy Management (PTM) platform is a proven purpose-built, enterprise-grade digital solution for advanced therapy data and supply chains, which will integrate with Ori’s platform to deliver a next-generation digital supply chain management system that supports therapies from clinical-phase to commercial distribution at scale.
“The pre-integration of Vineti’s Chain of Identity and Chain of Custody systems with the Ori full-stack platform is critical to help ensure our customers have full end-to-end visibility, control, and insights into their processes,” said Ori Biotech CEO Jason C. Foster. “The addition of established technologies in such a critical aspect of CGT manufacturing allows us to enable our partners across the industry to develop and commercialize therapies as safely, cost effectively, and quickly as possible to reach the large numbers of patients who need these therapeutic alternatives.”
“Advanced therapies are at a point where they require true industrialization, with the best digital tools and a connected ecosystem,” said Vineti CEO and co-founder Amy DuRoss. “We’re very excited to partner with Ori Biotech to deliver our shared next-generation vision and ultimately help breakthrough treatments get to patients faster.”
This partnership follows on from Ori’s continuous growth since closing a $30 million Series A funding round in 2020, and Vineti’s release of its PTM Essentials solution for advanced therapy clinical trials.
